Abstract | BACKGROUND: STUDY: We performed a longitudinal review of gastrointestinal endoscopy, pharmacy databases, and medical records of patients referred to our service over a period of 6 months for endoscopic evaluation of upper gastrointestinal bleeding, unexplained anemia, or abdominal pain. Data were collected and analyzed for 55 patients taking ticlopidine, 77 age- and gender-matched patients taking aspirin or NSAIDs, and 560 age- and gender-matched control patients not taking any of these medications. RESULTS: CONCLUSIONS: Patients taking ticlopidine are more likely to have endoscopic evidence of mucosal damage than matched control patients and are nearly as likely to have such damage as endoscopically evaluated patients taking aspirin or NSAIDs. However, these findings must be confirmed using prospective cohort data for patients in primary care settings, to avoid referral bias.
|
Authors | Rafiq A Sheikh, Patrick S Romano, Thomas P Prindiville, Shagufta Yasmeen, Walter Trudeau |
Journal | Journal of clinical gastroenterology
(J Clin Gastroenterol)
2002 May-Jun
Vol. 34
Issue 5
Pg. 529-32
ISSN: 0192-0790 [Print] United States |
PMID | 11960063
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Platelet Aggregation Inhibitors
- Ticlopidine
- Aspirin
|
Topics |
- Anemia
(chemically induced)
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Aspirin
(therapeutic use)
- Case-Control Studies
- Databases, Factual
- Esophagitis
(chemically induced)
- Female
- Gastric Mucosa
(drug effects)
- Gastritis
(chemically induced)
- Gastrointestinal Hemorrhage
(chemically induced)
- Humans
- Intestinal Mucosa
(drug effects)
- Longitudinal Studies
- Male
- Middle Aged
- Peptic Ulcer
(chemically induced)
- Platelet Aggregation Inhibitors
(adverse effects, therapeutic use)
- Prevalence
- Ticlopidine
(adverse effects, therapeutic use)
|